Sponsors & Partners
2026 conference
The 2026 Prader-Willi Research and Family Conference will be the year's landmark event, bringing together researchers, scientists, clinicians, families, and the wider disability and rare disease community.
The conference will showcase world-leading Australian research, highlight innovative clinical practices, and provide families with resources, workshops, and community connections. Alongside International plenary speakers, research symposiums, and a dedicated family program, the conference will feature special events including the Research Catalyst Dinner and a Cocktail Welcome Reception.
This is a unique opportunity to align your brand with groundbreaking research, clinical excellence, and a passionate, resilient community.
Current Sponsors & Partners
premier Sponsor
Brisbane Airport Conference Centre - located within the same precinct as the Pullman Hotel Brisbane Airport. It includes 1,800 square metres of dedicated conference, meeting and events space that can accommodate up to 300 people.
Brisbane Airport Conference Centre is the host for the 2026 Prader-Willi Research and Family Conference, Pathways Forward: Where Hope Ignites Innovation.
Champion Sponsor
About Aardvark Therapeutics, Inc.
Aardvark is a clinical-stage biopharmaceutical company developing novel, small-molecule therapeutics designed to suppress hunger for the treatment of Prader-Willi Syndrome (PWS) and metabolic diseases. Hunger, which is the discomfort from not having eaten recently, is a distinct neural signaling pathway separate from appetite, the reward-seeking desire for food. Our programs explore therapeutic applications in hunger-associated indications and potential complementary uses with anti-appetite therapies. Our lead compound, oral ARD-101, is in Phase 3 clinical development for the treatment of hyperphagia associated with PWS, a rare disease characterized by insatiable hunger. Aardvark is also developing ARD-201, a planned fixed-dose combination of ARD-101 with a DPP-4 inhibitor, through two separate Phase 2 trials with a goal of addressing some of the limitations of currently marketed GLP-1 therapies for obesity and obesity-related conditions. For more information, visit www.aardvarktherapeutics.com.
